Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
9 Meters Biopharma Inc (NMTR)  
$0.00 0.00 (0.00%) as of 4:30 Thu 3/28


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 12,960,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.000001 - $1.25
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   9 Meters Biopharma is a clinical-stage company. Co.'s product development pipeline include: Vurolenatide, which is a long-acting glucagon-like peptide-1 receptor agonist that combines exenatide with a proprietary extended half-life technology for treatment of short bowel syndrome; Larazotide, which is being developed for the treatment of celiac disease; NM-102, which is a small molecule peptide that is being developed as a potential microbiome modulator and is undergoing an indication selection process; and NM-003, which is a proprietary long-acting glucagon-like peptide-2 agonist with improved serum half-life compared with short-acting versions.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 472,383
Total Buy Value $0 $0 $0 $151,319
Total People Bought 0 0 0 3
Total Buy Transactions 0 0 0 5
Total Shares Sold 0 0 0 9,100
Total Sell Value $0 $0 $0 $11,011
Total People Sold 0 0 0 1
Total Sell Transactions 0 0 0 1
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 110
  Page 1 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sensenig Bethany Chief Financial Officer   •       –      –    2023-04-21 4 S $1.21 $11,011 D/D (9,100) 41,077 99%     
   Temperato John Chief Executive Officer   •       •      –    2023-03-27 4 A $0.00 $0 D/D 68,815 140,192     -
   Sensenig Bethany Chief Financial Officer   •       –      –    2023-03-27 4 A $0.00 $0 D/D 50,177 50,177     -
   Temperato John Chief Executive Officer   •       •      –    2022-07-06 4 B $0.23 $28,463 D/D 125,000 1,427,522 2.81 -49%     
   Sirgo Mark A Director   –       •      –    2022-07-01 4/A A $0.25 $42,963 D/D 175,000 1,560,428     -
   Sirgo Mark A Director   –       •      –    2022-07-01 4 B $0.25 $42,963 D/D 175,000 1,454,045 2.39 -53%     
   Constantino Michael T. Director   –       •      –    2022-05-23 4 B $0.48 $7,608 D/D 16,000 60,509 2.39 -52%     
   Temperato John Chief Executive Officer   •       •      –    2022-05-18 4 B $0.45 $22,285 D/D 50,000 1,302,522 2.81 -49%     
   Sirgo Mark A Director   –       •      –    2022-05-18 4 B $0.47 $50,000 D/D 106,383 1,385,428 2.39 -49%     
   Sirgo Mark A Director   –       •      –    2022-03-03 4 B $0.58 $50,002 D/D 86,450 1,279,045 2.39 -60%     
   Temperato John Chief Executive Officer   •       •      –    2022-03-03 4 B $0.56 $55,590 D/D 100,000 1,252,522 2.81 -60%     
   Sirgo Mark A Director   –       •      –    2021-12-02 4 B $0.89 $44,500 D/D 50,000 1,242,595 2.39 -42%     
   Sirgo Mark A Director   –       •      –    2021-11-18 4 B $1.06 $21,200 D/D 20,000 1,192,595 2.39 -43%     
   Temperato John Chief Executive Officer   •       •      –    2021-11-18 4 B $1.05 $52,500 D/D 50,000 1,152,522 2.81 -43%     
   Sitar Edward J Chief Financial Officer   •       –      –    2021-09-14 4 B $1.22 $18,300 D/D 15,000 194,338 2.74 -38%     
   Sirgo Mark A Director   –       •      –    2021-09-07 4 B $1.36 $99,999 D/D 73,529 1,172,595 2.39 -36%     
   Constantino Michael T. Director   –       •      –    2021-08-24 4 B $1.14 $20,520 D/D 18,000 52,108 2.39 -22%     
   Sirgo Mark A Director   –       •      –    2021-08-20 4 B $1.10 $27,500 D/D 25,000 1,099,066 2.39 -11%     
   Temperato John Chief Executive Officer   •       •      –    2021-08-18 4 B $1.05 $26,250 D/D 25,000 1,102,522 2.81 -10%     
   Orbimed Israel Biofund Gp Limited Partnership 10% Owner   –       –       •   2021-06-25 4 S $1.21 $19,347,750 I/I (15,989,876) 8,565,974 -6%     
   Orbimed Israel Biofund Gp Limited Partnership 10% Owner   –       –       •   2021-06-24 4 S $1.38 $440,572 I/I (319,255) 24,555,850 5%     
   Orbimed Israel Biofund Gp Limited Partnership 10% Owner   –       –       •   2021-06-23 4 S $1.36 $1,144,644 I/I (841,650) 24,875,105 6%     
   Orbimed Israel Biofund Gp Limited Partnership 10% Owner   –       –       •   2021-05-11 4 OE $0.62 $20,836 I/I 31,944 25,748,699     -
   Sirgo Mark A Director   –       •      –    2020-12-15 4 B $0.65 $150,000 D/D 230,769 774,066 2.39 66%     
   Temperato John Chief Executive Officer   •       •      –    2020-12-15 4 B $0.65 $100,000 D/D 153,846 977,522 2.81 66%     
  110 Records found
  1  2  3  4  5   
  Page 1 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us